Thank you Angus Liu and FierceBiotech for the conversation with our CEO, Greg Frost! #AACR2022 #celltherapy AACR: Exuma aims to be first to the clinic with under-the-skin cancer CAR cell therapy without complex manufacturing fiercebiotech.com/research/aacr-…

Thank you gail dutton and BioSpace for the conversation with our VP Oncology, Dr. Sid Kerkar AACR. #AACR2022 #CellTherapy biospace.com/article/exuma-…

Our VP Oncology,R&D, Dr. Sid Kerkar, enjoyed speaking to VJHemOnc about EXUMA Biotech's in vivo engineered CAR #GeneTherapy program (GCAR) AACR. vjhemonc.com/video/wihmxpqf…

#ICYMI Our VP Oncology, R&D, Dr. Sid Kerkar, spoke to VJHemOnc about EXUMA Biotech's novel #subcutaneous CAR-TaNK therapy for #hematological #tumors AACR. #aacr2022 vjhemonc.com/video/kh24rfml…

Our CEO Gregory Frost always enjoys catching up with Matthew Pillar BioProcess Online about EXUMA Biotech's novel #subcutaneous CAR-TaNK therapy for #hematological tumors & our in vivo engineered CAR #GeneTherapy program (GCAR).#biotech #oncology #CellTherapy bioprocessonline.com/doc/the-car-t-…

#ICYMI The CAR T Speed Show. Thank you, Matthew Pillar.

Our VP Oncology R&D, Dr. Sid Kerkar, enjoyed his in depth conversation with Oncology Tube on EXUMA Biotech's cell and gene therapy programs. #celltherapy #genetherapy #biotech

Our VP Oncology R&D, Dr. Sid Kerkar, is looking forward to next week's In Vivo Engineering of Therapeutic Cells Summit. For more details, check out our website. #invivo2022 👉exumabio.com/news/2022/07/e…

“Our CEO, Gregory Frost, enjoyed being back in person for this year’s (Biotechnology Innovation Organization) Biotechnology Innovation Organization Conference in sunny San Diego, and the conversation with colleagues at BIO’s China Summit.” #bio2022 #biotechnology #oncology #cellandgenetherapy

Our VP of Oncology, R&D, Dr. Sid Kerkar, is in Boston this week for the"In Vivo Engineering of Therapeutic Cells Summit." EXUMA Biotech's novel in vivo GCAR technology has the potential to overcome many barriers surrounding ex vivo CAR therapies. #invivo2022

EXUMA Biotech's VP of Oncology, R&D, Dr. Sid Kerkar, took a deep dive Tuesday into everything you need to know about CAR therapies, and how to make the switch from developing ex vivo to in vivo therapies. #invivo2022 #biotech #oncology #cellandgenetherapy

EXUMA Biotech's VP of Oncology, R&D, Dr. Sid Kerkar, is in #Boston this week to discuss the advantages and how to fast-track in vivo cell & gene therapies to the clinic. #biotech #oncology #invivo2022 #cellandgenetherapy

#ICYMI Our VP Oncology, R&D, Dr. Sid Kerkar, and Chief Business Officer, Gregory R Wade Ph.D., enjoyed the week. On this last day, Dr. Kerkar led a roundtable discussion, "Optimizing the In Vivo Approach: Considerations for Safety & Tolerability." #invivo2022

Our VP of R&D, Oncology, Dr. Sid Kerkar, and Sr. Dir. of Global QA, Michelle Andraza, join other industry leaders in #Boston this week to discuss the current state & future generations of cell & gene #immunotherapy at the 7th Annual CAR-TCR Summit. #CARTCR #cellandgenetherapy

Our Chairman and CEO, Dr. Gregory Frost, joined EmpoweredPatient on the #EmpoweredPatientPodcast to discuss innovation in immunotherapies and how our rPOC platform aims to eliminate lymphodepletion in CAR therapy #immunotherapy #cellandgenetherapy #cancer empoweredpatientradio.com/administering-…

Our VP of R&D, Oncology, Dr. Sid Kerkar, spoke to CGTLive® at the 7th Annual CAR-TCR Summit about how EXUMA's CAR-TaNK platforms aim to make CAR therapy safer and faster through our proprietary lentivector design #immunotherapy #cellandgenetherapy cgtlive.com/view/kerkar-md…

Our Chairman & CEO, Greg Frost, taps into his California roots on Tacos & Tech Podcast 🌮🤖🎙 to discuss his entrepreneurial journey, EXUMA's innovative technologies, & the best spots in the San Diego(ish) area to grab surf & turf tacos. #immunotherapy #carneasada tacosandtech.libsyn.com/developing-acc…

From everyone at EXUMA Biotech, we would like to send our warmest wishes for a happy, healthy, and prosperous Lunar New Year! #happylunarnewyear #yearoftherabbit

A great retrospective on the impact of #Herceptin on its silver anniversary, chaired by Dr. Michael Shepard at #AACR2023, while EXUMA CEO, Greg Frost, discussed employing CAR-T approaches as another potential advancement in #HER2-targeted therapy. aacrmeetingnews.org/news/symposium…

粽叶飘香五月五，喜乐安康共端午。埃秀马生物祝大家端午安康